All posts by: ashvatthaadmin

Ashvattha announced results from a preclinical study demonstrating targeting of HDs to renal macrophages after acute ischemia in a diabetic animal model, at the American Society of Nephrology (ASN) Kidney Week 2020, held virtually October 19-25, 2020....
Continue Reading →
Ashvattha Therapeutics announced the appointment of George G. Montgomery to its board of directors. Montgomery brings more than 30 years of extensive experience as an investor, entrepreneur and investment banker across diverse healthcare sectors....
Continue Reading →
Jeffrey Cleland, Ph.D., chairman, chief executive officer and president of Ashvattha Therapeutics, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020....
Continue Reading →
Orpheris, a subsidiary of Ashvattha, announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe COVID-19. ...
Continue Reading →
Orpheris, a subsidiary of Ashvattha, announced results from a Phase 1 single administration study evaluating the subcutaneous (SC) formulation of OP-101 (4 or 8 mg/kg) in healthy volunteers....
Continue Reading →
Orpheris, a subsidiary of Ashvattha, announced the FDA has agreed to a Phase 2 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of OP-101 in patients with severe COVID-19...
Continue Reading →
Ashvattha Therapeutic has been selected to present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in June, 2020....
Continue Reading →
Company to develop subcutaneously administered dendrimer-based anti-VEGF therapy with selective targeting in wet AMD. Potential therapeutic may offer significant opportunities for degenerative retinal diseases such as wet AMD and diabetic retinopathy, and may reduce significant side effects associated with...
Continue Reading →